Posted by Michael Wonder on 06 Jun 2025
Biogen disappointed by INESSS recommendation on Skyclarys and its impact on Quebec patients with Friedreich ataxia
5 June 2025 - Biogen Canada is disappointed by INESSS's recommendation against listing Skyclarys (omaveloxolone), despite its therapeutic potential for individuals living with Friedreich's ataxia — a community in urgent need of treatment options.
A decision to not reimburse Skyclarys would leave individuals living with Friedreich's ataxia in Quebec without public access to the only approved treatment for this rare, progressive, and life-shortening neurodegenerative disease – despite a clear and ongoing medical need.
